Efficacy and safety of implantable vascular support in the treatment of arteriovenous fistula: A single-arm meta-analyses

• Published in: The journal of vascular access 2024-01, p.11297298231223537-11297298231223537
• Main Authors: Li, Xuanwei, Ma, Congyuan, Li, Wenlai, Li, Yue, Zhang, Meng, Zhu, Ping
• Format: Article
• Language: English
• ISSN: 1129-7298; 1724-6032
• DOI: 10.1177/11297298231223537

VasQ (Laminate Medical Technologies, Israel) is an external support device for autologous arteriovenous fistula (AVF) designed to improve anastomotic blood flow and reduce neointimal hyperplasia. However, different studies have shown that the efficacy of the VasQ device in improving AVF is inconsistent. The purpose of this study was to conduct a meta-analysis to further evaluate the efficacy and safety of the VasQ device. Two reviewers independently searched studies published in PubMed, EMBASE, Cochrane, Web of Science, CNKI, and Wan Fang databases from inception to 2023. The Cochrane Systematic Evaluation Bias Risk Tool Version 1 was used to assess the risk of RCTS bias. The ROBINS-I tool was used to assess the risk of bias in non-randomized studies. A Single-arm meta-analysis was performed, and a random effects model was used for all analyses. We identified six trials involving 146 patients and conducted a meta-analysis. The results showed that after 6 months of VasQ device treatment, the primary patency rate of AVF was [76.4% (95%CI: 0.608-0.920),